Johnson & Johnson keeps the heat on Tremfya's rivals with at-home injector nod

Johnson & Johnson’s Tremfya put a key rival on defense late last year with head-to-head data, and now it’s keeping the heat on its psoriasis competitors—including Novartis' Cosentyx and Eli Lilly's Taltz, which beat it to market.